Drug intelligence / Profile preview

AKG-230

Development stage: Preclinical
Lead developer: Akagera Medicines
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

AKG-230 is a preclinical-stage prophylactic mRNA vaccine being developed by Akagera Medicines for the prevention of Human Immunodeficiency Virus (HIV) infection. The vaccine utilizes mRNA technology to induce an immune response against HIV antigens, leveraging the company's expertise in delivery systems. As of early 2024, the program remains in the preclinical phase of development as part of Akagera's infectious disease vaccine pipeline.

Beyond the preview

Go deeper on AKG-230.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKG-230.

Explore the full profile